Yang Li1, Yu Wang1, Zhuoyue Wang1, Danhui Yi1, Shuangge Ma1,2. 1. School of Statistics and The Center for Applied Statistics, Renmin University of China, 59 Zhongguancun Ave. Beijing, 100872, China. 2. School of Public Health, Yale University, 60 College ST, New Haven CT, 06520, USA.
Abstract
BACKGROUND: NHL (non-Hodgkin lymphoma) consists of over 60 subtypes, ranging from slow-growing to very aggressive. The three largest subtypes are DLBCL (diffuse large B-cell lymphoma), FL (follicular lymphoma), and CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma). For each subtype, different racial groups have different presentations, etiologies, and prognosis patterns. METHODS: SEER (Surveillance, Epidemiology, and End Results) data on DLBCL, FL, and CLL/SLL patients diagnosed between 1992 and 2010 were analyzed. Racial groups studied included NHW (non-Hispanic whites), HW (Hispanic whites), blacks, and API (Asians and Pacific Islanders). Patient characteristics, age-adjusted incidence rate, and survival were compared across races. Stratification and multivariate analysis were conducted. RESULTS: There are significant racial differences for patients' characteristics, including gender, age at diagnosis, stage, lymph site, and age, and the patterns vary across subtypes. NHWs have the highest incidence rates for all three subtypes, followed by HWs (DLBCL and FL) and blacks (CLL/SLL). The dependence of the incidence rate on age and gender varies across subtypes. For all three subtypes, NHWs have the highest five-year relative survival rates, followed by HWs. When stratified by stage, racial difference is significant in multiple multivariate Cox regression analyses. CONCLUSIONS: Racial differences exist among DLBCL, FL, and CLL/SLL patients in the U.S. in terms of characteristics, incidence, and survival. The patterns vary across subtypes. More data collection and analysis are needed to more comprehensively describe and interpret the across-race and subtype differences.
BACKGROUND: NHL (non-Hodgkin lymphoma) consists of over 60 subtypes, ranging from slow-growing to very aggressive. The three largest subtypes are DLBCL (diffuse large B-cell lymphoma), FL (follicular lymphoma), and CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma). For each subtype, different racial groups have different presentations, etiologies, and prognosis patterns. METHODS: SEER (Surveillance, Epidemiology, and End Results) data on DLBCL, FL, and CLL/SLLpatients diagnosed between 1992 and 2010 were analyzed. Racial groups studied included NHW (non-Hispanic whites), HW (Hispanic whites), blacks, and API (Asians and Pacific Islanders). Patient characteristics, age-adjusted incidence rate, and survival were compared across races. Stratification and multivariate analysis were conducted. RESULTS: There are significant racial differences for patients' characteristics, including gender, age at diagnosis, stage, lymph site, and age, and the patterns vary across subtypes. NHWs have the highest incidence rates for all three subtypes, followed by HWs (DLBCL and FL) and blacks (CLL/SLL). The dependence of the incidence rate on age and gender varies across subtypes. For all three subtypes, NHWs have the highest five-year relative survival rates, followed by HWs. When stratified by stage, racial difference is significant in multiple multivariate Cox regression analyses. CONCLUSIONS: Racial differences exist among DLBCL, FL, and CLL/SLLpatients in the U.S. in terms of characteristics, incidence, and survival. The patterns vary across subtypes. More data collection and analysis are needed to more comprehensively describe and interpret the across-race and subtype differences.
Authors: Chadi Nabhan; Michelle Byrtek; Michael D Taylor; Jonathan W Friedberg; James R Cerhan; John D Hainsworth; Thomas P Miller; Jamie Hirata; Brian K Link; Christopher R Flowers Journal: Cancer Date: 2012-03-20 Impact factor: 6.860
Authors: Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet Journal: Blood Date: 2005-09-08 Impact factor: 22.113
Authors: Rami S Komrokji; Najla H Al Ali; M S Beg; Malek M Safa; Dana Rollison; Mohamed Kharfan-Dabaja; Celeste Bello; Jennifer Cultrera; Lubomir Sokol; Javier Pinilla-Ibarz; Eduardo M Sotomayor Journal: Clin Lymphoma Myeloma Leuk Date: 2011-04-20
Authors: Lindsay M Morton; Patricia Hartge; Theodore R Holford; Elizabeth A Holly; Brian C H Chiu; Paolo Vineis; Emanuele Stagnaro; Eleanor V Willett; Silvia Franceschi; Carlo La Vecchia; Ann Maree Hughes; Wendy Cozen; Scott Davis; Richard K Severson; Leslie Bernstein; Susan T Mayne; Fred R Dee; James R Cerhan; Tongzhang Zheng Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-04 Impact factor: 4.254
Authors: Anan Szumera-Ciećkiewicz; K Gałązka; J Szpor; G Rymkiewicz; D Jesionek-Kupnicka; A Gruchała; B Ziarkiewicz-Wróblewska; G Poniatowska-Broniek; S Demczuk; M Prochorec-Sobieszek Journal: Int J Clin Exp Pathol Date: 2014-05-15
Authors: Jie Zhang; Zhi-Wei Ye; Danyelle M Townsend; Chanita Hughes-Halbert; Kenneth D Tew Journal: Adv Cancer Res Date: 2019-04-23 Impact factor: 6.242
Authors: Gerardo Colon-Otero; Scott A Van Wier; Greg J Ahmann; Esteban Braggio; Monica L Albertie; Jennifer A Weis; Sikander Ailawadhi; James R Cerhan; Prakash Vishnu; Matthew S Jorgensen; James M Foran; Colleen S Thomas; Rafael Fonseca Journal: Ann Hematol Date: 2016-10-12 Impact factor: 3.673
Authors: Martin Felices; Behiye Kodal; Peter Hinderlie; Michael F Kaminski; Sarah Cooley; Daniel J Weisdorf; Daniel A Vallera; Jeffrey S Miller; Veronika Bachanova Journal: Blood Adv Date: 2019-03-26
Authors: Thomas J Kipps; Freda K Stevenson; Catherine J Wu; Carlo M Croce; Graham Packham; William G Wierda; Susan O'Brien; John Gribben; Kanti Rai Journal: Nat Rev Dis Primers Date: 2017-01-19 Impact factor: 52.329
Authors: Erin E Kent; Nancy Breen; Denise R Lewis; Janet S de Moor; Ashley Wilder Smith; Nita L Seibel Journal: Cancer Causes Control Date: 2015-06-18 Impact factor: 2.506
Authors: Amy A Ayers; Lin Lyu; Kaylin Dance; Kevin C Ward; Christopher R Flowers; Jean L Koff; Lauren E McCullough Journal: Clin Lymphoma Myeloma Leuk Date: 2019-06-26